Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
President Trump also said he is "not looking for a partial deal" with Beijing, moving away from his suggestion last week that he would consider an "interim deal."Politicsread more
Progress on trade talks will determine how far market will move above new highs.Trader Talk with Bob Pisaniread more
For investors taking a breather from the chaos in August, buckle up as the market is about go crazy again, Goldman Sachs warned.Marketsread more
Palantir Technologies is targeting a valuation of at least $26 billion in a private fundraising round, the first for the Peter Thiel-backed data analytics startup in four...Wall Streetread more
Michael Pack, a conservative filmmaker linked to Steve Bannon, saw at least $1.6 million in donations from his nonprofit sent into the coffers of his independent production...Politicsread more
The New England Patriots released Antonio Brown just 11 days after signing the wide receiver. The NFL Super Bowl champion team initially had kept him in the face of a rape...Sportsread more
The Wall Street Journal's report came as a top Ukraine official said President Donald Trump "is looking" for Ukraine officials to investigate business dealings of Biden's son...Politicsread more
A tour bus carrying Chinese-speaking tourists crashed near a national park in southern Utah, killing at least four people and critically injuring up to 15 others, authorities...U.S. Newsread more
Gun maker Colt announced Thursday that it will halt its production of AR-15 rifles for civilian sales, but the news might not be as exciting for gun control advocates as it...Guns and Weaponsread more
As thousands of people across the world participate in the Global Climate Strike, several Democratic presidential candidates have shared how they will take aggressive action...Scienceread more
"I like nothing more than to find companies that give you lots of ways to win," Cramer said. "That's this stock, to a tee."
The Mad Money host was talking about Johnson & Johnson, a stock that he suggests buying if the overall market declines.
Long-term Cramer sees many catalysts that should drive Johnson & Johnson higher. They follow:
"JNJ has the best organic growth of any of the major drug companies, and its accelerating. That's what's so crucial. This market thrives on growth," Cramer said.
"It has the best balance sheet in the industry," Cramer insisted. And all that cash allows JNJ to move very strategically."
For example, JNJ has a piece of "a revolutionary anti-blood cancer drug, which which has shown an incredible 68% response rate on treatment resistant non-hodgkins lymphoma. This drug alone could do as much as $6.5 billion in sales in just a few years."
The consumer products division has some of the best known products on the market including the now rejuvenated Tylenol business," Cramer noted.
Under Alex Gorsky, "Johnson & Johnson has gone from being poorly managed to being among the best managed companies in health care."
Read More from Mad Money with Jim Cramer
What's driving Google? Cramer explains
Why Cramer sees upside in Apple
Amid pullback, this stock a buy: Cramer
All told, Cramer sees every reason for shares to climb. It's could attract growth investors, defensive investors, those looking for a spin-off and others betting on promising new treatments.
"I know the stock's up 31% since the year began, but I think that's just the beginning. Due to the catalysts outlined above there are just too many ways to win. "I suspect a multi-year move lies ahead," Cramer said. "This may be the best buy and hold (and Cramer doesn't like that term) on the entire Big Board."
Call Cramer: 1-800-743-CNBC
Questions for Cramer? firstname.lastname@example.org
Questions, comments, suggestions for the "Mad Money" website? email@example.com